Aggregator
Conformational diversity and fully opening mechanism of native NMDA receptor
Maximizing perovskite electroluminescence with ordered 3D/2D heterojunction
Transmission of MPXV from fire-footed rope squirrels to sooty mangabeys
CSN5i-3 is an orthosteric molecular glue inhibitor of COP9 signalosome
Aluminium redox catalysis enables cyclotrimerization of alkynes
Tiny robot fish could swim through the body powered by ultrasound
An ancient Roman game board’s secrets are revealed — with AI’s help
These hungry immune cells tidy sleeping flies’ brains
Author Correction: Inference and reconstruction of the heimdallarchaeial ancestry of eukaryotes
Transferable enantioselectivity models from sparse data
Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer’s disease
Implementing a nationwide healthy longevity program for older adults
What drugs are safe during pregnancy? There’s a shocking lack of data
My professor said ‘Black people are not interested in the environment’. I set out to prove him wrong
Pre-Incans collected seabird poop from remote islands to use as fertilizer
Guano-based agriculture became highly prized in the Inca empire
Japan’s election result could bring a research funding boost
Landslide win by Liberal Democratic Party clears path for targeted R&D spending plan
Blood-based biomarkers for Alzheimer's disease: Advances in early detection and monitoring of age-related neurodegeneration
Alzheimer's disease (AD) presents a critical global challenge, accounting for over 60 % of the 57 million current dementia cases worldwide, with prevalence projected to exceed 100 million by 2050. Traditional diagnostic approaches, such as cerebrospinal fluid (CSF) analysis and neuroimaging are constrained by invasiveness, high costs, and limited accessibility, particularly problematic in aging population where early detection is crucial for effective intervention. This review synthesizes recent...
Should all MCI with Alzheimer's biological diagnosis receive anti-amyloid therapy?
Our perspective addresses one of the most pressing and timely debates in contemporary neurology and health policy: whether the recent approval of anti-amyloid monoclonal antibodies for Alzheimer's disease should extend to all individuals with mild cognitive impairment (MCI; a large population of tens of millions of individuals worldwide mainly represented in Countries with aged population) who test positive for amyloid biomarkers, despite wide variability in prognosis and therapeutic response...
Mitochondrial DNA drives NLRP3-IL-1beta axis activation in microglia by binding to NLRP3, leading to neurodegeneration in Parkinson's disease models
Dysregulated mitochondrial DNA (mtDNA) promotes inflammatory response and disease progression. However, the mechanism and role of mtDNA-mediated inflammatory activation in the pathogenesis of Parkinson's disease (PD) are not yet clear. This study demonstrates that the injection of mtDNA into the substantia nigra pars compacta induces PD pathology in mice, characterized by the loss of dopaminergic (DA) neurons and the activation of microglia. Transcriptomic profiling of magnetic-activated cell...
Impaired BDNF-TrkB trafficking and signalling in Down syndrome basal forebrain neurons
Brain derived neurotrophic factor (BDNF) and its receptor tropomyosin-related kinase B (TrkB) play crucial roles in neuronal development, synaptic transmission, and neuroplasticity. Deficits in BDNF/TrkB signalling and trafficking have been identified in several neurodegenerative diseases, including Alzheimer's disease (AD). Individuals with Down syndrome (DS) are at an increased risk of developing AD compared to the general population. Basal forebrain neurons (BFNs) are among the first to...